Arcus Biosciences, Inc. Equity Method Investments
Arcus Biosciences, Inc. (RCUS) had Equity Method Investments of $0 as of 2019-09-30, per its 10-Q filed 2019-11-05.
Discontinued › Balance Sheet › Assets
us-gaap:EquityMethodInvestments · last filed 2020-03-05
- 2019-09-30: Equity Method Investments $0.00.
- 2019-06-30: Equity Method Investments $357.00K.
- 2019-03-31: Equity Method Investments $770.00K.
- 2018-12-31: Equity Method Investments $1.20M.
| Period end | Equity Method Investments |
|---|---|
| 2019-09-30 | $0.00 10-Q · filed 2019-11-05 |
| 2019-06-30 | $357.00K 10-Q · filed 2019-08-06 |
| 2019-03-31 | $770.00K 10-Q · filed 2019-05-02 |
| 2018-12-31 | $1.20M 10-K · filed 2020-03-05 |
| 2018-09-30 | $1.52M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $1.71M 10-Q · filed 2018-08-06 |
| 2018-03-31 | $515.00K 10-Q · filed 2018-05-09 |
| 2017-12-31 | $682.00K 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |